p.116 抽出テキスト

and 2016–2018. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging 2017;18:1073–1089. https://doi.org/10.1093/ehjci/jex146 850. Fatkin D, Huttner IG, Kovacic JC, Seidman JG, Seidman CE. Precision medicine in the management of dilated cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;74:2921–2938. https://doi.org/10.1016/j.jacc.2019.10.011 851. Merlo M, Cannata A, Sinagra G. Dilated cardiomyopathy: a paradigm of revolution in medicine. J Clin Med 2020;9:3385. https://doi.org/10.3390/jcm9113385 852. Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553–576. https://doi.org/ 10.1002/ejhf.1461 853. Verdonschot JAJ, Hazebroek MR, Krapels IPC, Henkens M, Raafs A, Wang P, et al. Implications of genetic testing in dilated cardiomyopathy. Circ Genom Precis Med 2020;13:476–487. https://doi.org/10.1161/CIRCGEN.120.003031 854. Hey TM, Rasmussen TB, Madsen T, Aagaard MM, Harbo M, Molgaard H, et al. Clinical and genetic investigations of 109 index patients with dilated cardiomyopathy and 445 of their relatives. Circ Heart Fail 2020;13:e006701. https://doi.org/10.1161/ CIRCHEARTFAILURE.119.006701 855. Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, et al. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant 2016;35:625–635. https://doi.org/10.1016/j.healun.2015. 12.014 856. van der Meulen MH, Herkert JC, den Boer SL, du Marchie Sarvaas GJ, Blom N, Ten Harkel ADJ, et al. Genetic evaluation of a nation-wide Dutch pediatric DCM cohort: the use of genetic testing in risk stratification. Circ Genom Precis Med 2022;15: e002981. https://doi.org/10.1161/CIRCGEN.120.002981 857. Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, et al. Genetic causes of cardiomyopathy in children: first results from the pediatric cardiomyopathy genes study. J Am Heart Assoc 2021;10:e017731. https://doi.org/10.1161/JAHA.120. 017731 858. Escobar-Lopez L, Ochoa JP, Royuela A, Verdonschot JAJ, Dal Ferro M, Espinosa MA, et al. Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2022;80:1115–1126. https://doi.org/10.1016/j.jacc.2022. 06.040 859. Cannata A, Merlo M, Dal Ferro M, Barbati G, Manca P, Paldino A, et al. Association of titin variations with late-onset dilated cardiomyopathy. JAMA Cardiol 2022;7:371–377. https://doi.org/10.1001/jamacardio.2021.5890 860. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225–237. https://doi.org/10.1056/NEJMoa043399 861. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375:1221–1230. https://doi.org/10.1056/NEJMoa1608029 862. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017;136:1772–1780. https://doi. org/10.1161/CIRCULATIONAHA.117.028829 863. Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, Alhussein M, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart 2018;104:230–236. https://doi.org/10.1136/heartjnl- 2017-311430 864. Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872–1884. https://doi.org/10.1161/CIRCULATIONAHA.119. 044934 865. Barriales-Villa R, Ochoa JP, Larranaga-Moreira JM, Salazar-Mendiguchia J, Diez-Lopez C, Restrepo-Cordoba MA, et al. Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. Rev Esp Cardiol (Engl Ed) 2021;74:216–224. https://doi.org/10.1016/j.recesp.2020.03.002 866. Gigli M, Stolfo D, Graw SL, Merlo M, Gregorio C, Nee Chen S, et al. Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants. Circulation 2021;144:1600–1611. https://doi.org/10.1161/ CIRCULATIONAHA.121.053521 867. Akhtar MM, Lorenzini M, Pavlou M, Ochoa JP, O’Mahony C, Restrepo-Cordoba MA, et al. Association of left ventricular systolic dysfunction among carriers of truncating variants in filamin C with frequent ventricular arrhythmia and end-stage heart failure. JAMA Cardiol 2021;6:891–901. https://doi.org/10.1001/jamacardio.2021.1106 868. Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young T-L, et al. Long-term clinical outcome of arrhythmogenic right ventricular cardiomyopathy in individuals with a p.S358L mutation in TMEM43 following implantable cardioverter defibrillator therapy. Circ Arrhythm Electrophysiol 2016;9:e003589. https://doi.org/10.1161/ CIRCEP.115.003589 869. Hey TM, Rasmussen TB, Madsen T, Aagaard MM, Harbo M, Molgaard H, et al. Pathogenic RBM20-variants are associated with a severe disease expression in male patients with dilated cardiomyopathy. Circ Heart Fail 2019;12:e005700. https://doi. org/10.1161/CIRCHEARTFAILURE.118.005700 870. Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA, et al. Prevalence and prognostic impact of pathogenic variants in patients with dilated cardiomyopathy referred for ventricular tachycardia ablation. JACC Clin Electrophysiol 2020;6:1103–1114. https://doi.org/10.1016/j.jacep.2020.04.025 871. Rootwelt-Norberg C, Christensen AH, Skjolsvik ET, Chivulescu M, Vissing CR, Bundgaard H, et al. Timing of cardioverter-defibrillator implantation in patients with cardiac laminopathies–external validation of the LMNA-risk ventricular tachyarrhythmia calculator. Heart Rhythm 2023;20:423–429. https://doi.org/10.1016/j.hrthm.2022. 11.024 872. Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circ Heart Fail 2020;13:e006832. https://doi.org/10.1161/ CIRCHEARTFAILURE.119.006832 873. Mirelis JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, Villacorta E, Navarro M, et al. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2022;24: 1183–1196. https://doi.org/10.1002/ejhf.2514 874. Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2021;77:2890–2905. https://doi. org/10.1016/j.jacc.2021.04.030 875. Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol 2001;24: 1623–1630. https://doi.org/10.1046/j.1460-9592.2001.01623.x 876. Merino JL, Carmona JR, Fernandez-Lozano I, Peinado R, Basterra N, Sobrino JA. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation 1998;98:541–546. https://doi.org/10.1161/01.CIR. 98.6.541 877. Russo V, Papa AA, Rago A, Ciardiello C, Martino AM, Stazi A, et al. Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the predictive role of programmed ventricular stimulation. Europace 2022;24:1148–1155. https://doi.org/10.1093/europace/euab282 878. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012;59:493–500. https://doi.org/10. 1016/j.jacc.2011.08.078 879. Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Isnard R, et al. External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. Eur J Heart Fail 2019;21:253–254. https://doi.org/10.1002/ejhf.1384 880. Ader F, De Groote P, Reant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C, et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clin Genet 2019;96:317–329. https://doi.org/10. 1111/cge.13594 881. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young T-L, McKenna WJ, et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43. Clin Genet 2013;83:321–331. https://doi.org/10.1111/j.1399-0004.2012.01919.x 882. van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14: 1199–1207. https://doi.org/10.1093/eurjhf/hfs119 883. van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet 2014;7:455–465. https://doi.org/10. 1161/CIRCGENETICS.113.000374 884. Hallstrom AP, Greene HL, Wyse DG, Zipes D, Epstein AE, Domanski MJ, et al. Antiarrhythmics Versus Implantable Defibrillators (AVID)–rationale, design, and methods. Am J Cardiol 1995;75:470–475. https://doi.org/10.1016/S0002-9149(99) 80583-9 885. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart 2018;104:144–150. https://doi.org/10.1136/heartjnl-2016-310850 886. Jorda P, Toro R, Diez C, Salazar-Mendiguchia J, Fernandez-Falgueras A, Perez-Serra A, et al. Malignant arrhythmogenic role associated with RBM20: a comprehensive interpretation focused on a personalized approach. J Pers Med 2021;11:130. https://doi. org/10.3390/jpm11020130 887. Hasselberg NE, Edvardsen T, Petri H, Berge KE, Leren TP, Bundgaard H, et al. Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects. Europace 2014;16:563–571. https://doi.org/10.1093/europace/ eut291 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026